Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Generic ranitidine

Executive Summary

Generic ranitidine: Appeals court will hold emergency hearing July 22 to reconsider July 9 injunction preventing FDA from approving Novopharm's ANDA in time for a July 10 launch ("The Pink Sheet" July 14, T&G-1). Should the stay remain in place, the earliest FDA could theoretically approve a ranitidine ANDA would be Aug. 29 -- the date it determined Genpharm's generic exclusivity period will expire -- unless Genpharm resolves the patent suit brought by Glaxo or licenses its exclusivity to another firm with tentative approval...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel